PRN Archives - BioTuesdays

Executive Moves

Tom Tamberrino joins Profound as new CCO ahead of TULSA reimbursement going into effect at the start of 2025

Profound Medical (NASDAQ:PROF; TSX:PRN) announced the appointment of Tom Tamberrino as chief commercial officer (CCO). Abbey Goodman, the current CCO, will now lead strategic partnerships and continue to report to CEO...

October 17, 2024

Developments

Profound’s PRO-Talk Live! 2024 spotlights the future of prostate disease care with TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) hosted its second PRO-Talk Live! educational event, by physicians for physicians, in Las Vegas this past weekend. The event featured a prestigious panel of experts, innovators...

September 16, 2024

Markets

Lake Street starts Profound Medical at Buy; PT $16.50

Lake Street initiated coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and $16.50 price target. The stock closed at $10.19 on July 22. Analyst Ben Haynor writes that with reimbursement of TULSA...

July 23, 2024

Markets

Stifel upgrades Profound Medical to buy on CMS reimbursement; PT to $12

After market close today, Stifel upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “buy” from “hold” and raised its price target to $12 from $9 in response to the U.S. Centers for Medicare and Medicaid Services (CMS)...

July 15, 2024

Developments

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral...

July 12, 2024

Developments

Profound Medical receives FDA 510(k) clearance for ‘Contouring Assistant’ AI module enabling creation of automated TULSA treatment plan

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it has received FDA 510(k) clearance for its second TULSA-AI module, Contouring Assistant, a machine learning-based prostate segmentation tool, for use in...

May 14, 2024

Developments

Profound Medical highlights TULSA’s potential to become a mainstream treatment modality across the entire prostate disease spectrum

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that a total of 25 clinical presentations highlighting TULSA procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer...

May 6, 2024

Developments

Profound Medical in collaboration with Siemens Healthineers to expand access to the TULSA procedure to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced a non-exclusive collaboration with Siemens Healthineers (XETRA:SHL) aimed at laying the groundwork for Profound to begin marketing a complete therapeutics solution...

February 28, 2024

Developments

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

Profound Medical (NASDAQ:PROF; TSX:PRN) reported that the U.S. Centers for Medicare and Medicaid Services (CMS) has expanded TULSA’s HCPCS C code, C9734, for use in the ambulatory surgical center (ASC) setting...

November 3, 2023

Developments

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO technology was featured as a medical breakthrough in an Oct. 13 AARP article. The article introduces 57-year-old Tommy Saul, who was diagnosed with prostate cancer in...

October 13, 2023

Tag - PRN

Tom Tamberrino joins Profound as new CCO ahead of TULSA reimbursement going into effect at the start of 2025

Profound’s PRO-Talk Live! 2024 spotlights the future of prostate disease care with TULSA-PRO

Lake Street starts Profound Medical at Buy; PT $16.50

Stifel upgrades Profound Medical to buy on CMS reimbursement; PT to $12

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Profound Medical receives FDA 510(k) clearance for ‘Contouring Assistant’ AI module enabling creation of automated TULSA treatment plan

Profound Medical highlights TULSA’s potential to become a mainstream treatment modality across the entire prostate disease spectrum

Profound Medical in collaboration with Siemens Healthineers to expand access to the TULSA procedure to treat prostate disease

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

Profound Medical’s TULSA-PRO prostate cancer treatment featured by AARP as medical breakthrough

General

More